July 14, 2026 04:32 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal CM Suvendu Adhikari backs move to stop entry to Bankra Mosque inside Kolkata airport operational area | Big win for Vijay government! Supreme Court stays Madras HC's cow slaughter ban in Tamil Nadu | Badrinath Temple donation theft case: Key accused Pramod Nautiyal arrested in major breakthrough | 'Citizenship must be decided fairly': Supreme Court quashes Gauhati HC order declaring 27 as foreigners | 'Highway blocked, stones pelted, cops injured': BJP faces open revolt in Madhya Pradesh over Narottam Mishra ticket snub | Two Kolkata Police DCPs suspended over alleged remarks against Bengal CM Suvendu Adhikari | Bail to Bloodbath: Telangana man allegedly kills wife, kids and teen who accused him of sexual harassment | Prakash Raj gets bail in multiple voter registration case linked to 2019 polls | ED raids Shekhar Suman associate's premises in FEMA case; phone allegedly thrown from 13th floor | 'Candidate fled': Prashant Kishor jibes BJP over Bankipur nominee change
Pixabay

First phase trial of India's COVID-19 vaccine Covaxin begins on 375 people: Report 

| @indiablooms | Jul 18, 2020, at 03:10 pm

New Delhi: India's Bharat Biotech International Limited, which claimed to have created the country's first potential indigenous coronavirus disease (Covid-19) vaccine, has said the first phase of testing it on 375 people has started, media reports said.

Hindustan, Hindustan Time’s sister publication, reported that Bharat Biotech has said that human trials of Covaxin started on July 15. The Hyderabad-based pharmaceutical company has jointly developed the vaccine with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

Twelve hospitals in different parts of the country are carrying out this test, reports Hindustan Times.

  The indigenous, inactivated vaccine has been developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.